299660 — Cellid Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeSmall CapSucker Stock

Annual income statement for Cellid Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	ARS	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	0	909	480	0	4,165
Cost of Revenue
Gross Profit	0	909	155	0	705
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	5,287	13,920	15,391	11,904	15,952
Operating Profit	-5,287	-13,011	-14,911	-11,904	-11,787
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-4,126	-13,071	-22,865	-11,611	-12,259
Provision for Income Taxes
Net Income After Taxes	-4,126	-13,071	-22,865	-11,611	-12,259
Net Income Before Extraordinary Items
Net Income	-4,126	-13,071	-22,865	-11,611	-12,259
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-4,126	-13,071	-22,865	-11,611	-12,259
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-332	-1,044	-1,823	-883	-671
Dividends per Share